PDF(Pubmed)
Abstract：
UNASSIGNED: Diabetes mellitus is frequently associated with foot ulcers, which pose significant health risks and complications. Impaired wound healing in diabetic patients is attributed to multiple factors, including hyperglycemia, neuropathy, chronic inflammation, oxidative damage, and decreased vascularization.
UNASSIGNED: To address these challenges, this project aims to develop bioactive, fast-dissolving nanofiber dressings composed of polyvinylpyrrolidone loaded with a combination of an antibiotic (moxifloxacin or fusidic acid) and anti-inflammatory drug (pirfenidone) using electrospinning technique to prevent the bacterial growth, reduce inflammation, and expedite wound healing in diabetic wounds.
UNASSIGNED: The fabricated drug-loaded fibers exhibited diameters of 443 ± 67 nm for moxifloxacin/pirfenidone nanofibers and 488 ± 92 nm for fusidic acid/pirfenidone nanofibers. The encapsulation efficiency, drug loading and drug release studies for the moxifloxacin/pirfenidone nanofibers were found to be 70 ± 3% and 20 ± 1 µg/mg, respectively, for moxifloxacin, and 96 ± 6% and 28 ± 2 µg/mg, respectively, for pirfenidone, with a complete release of both drugs within 24 hours, whereas the fusidic acid/pirfenidone nanofibers were found to be 95 ± 6% and 28 ± 2 µg/mg, respectively, for fusidic acid and 102 ± 5% and 30 ± 2 µg/mg, respectively, for pirfenidone, with a release rate of 66% for fusidic acid and 80%, for pirfenidone after 24 hours. The efficacy of the prepared nanofiber formulations in accelerating wound healing was evaluated using an induced diabetic rat model. All tested formulations showed an earlier complete closure of the wound compared to the controls, which was also supported by the histopathological assessment. Notably, the combination of fusidic acid and pirfenidone nanofibers demonstrated wound healing acceleration on day 8, earlier than all tested groups.
UNASSIGNED: These findings highlight the potential of the drug-loaded nanofibrous system as a promising medicated wound dressing for diabetic foot applications.
UNASSIGNED: To address these challenges, this project aims to develop bioactive, fast-dissolving nanofiber dressings composed of polyvinylpyrrolidone loaded with a combination of an antibiotic (moxifloxacin or fusidic acid) and anti-inflammatory drug (pirfenidone) using electrospinning technique to prevent the bacterial growth, reduce inflammation, and expedite wound healing in diabetic wounds.
UNASSIGNED: The fabricated drug-loaded fibers exhibited diameters of 443 ± 67 nm for moxifloxacin/pirfenidone nanofibers and 488 ± 92 nm for fusidic acid/pirfenidone nanofibers. The encapsulation efficiency, drug loading and drug release studies for the moxifloxacin/pirfenidone nanofibers were found to be 70 ± 3% and 20 ± 1 µg/mg, respectively, for moxifloxacin, and 96 ± 6% and 28 ± 2 µg/mg, respectively, for pirfenidone, with a complete release of both drugs within 24 hours, whereas the fusidic acid/pirfenidone nanofibers were found to be 95 ± 6% and 28 ± 2 µg/mg, respectively, for fusidic acid and 102 ± 5% and 30 ± 2 µg/mg, respectively, for pirfenidone, with a release rate of 66% for fusidic acid and 80%, for pirfenidone after 24 hours. The efficacy of the prepared nanofiber formulations in accelerating wound healing was evaluated using an induced diabetic rat model. All tested formulations showed an earlier complete closure of the wound compared to the controls, which was also supported by the histopathological assessment. Notably, the combination of fusidic acid and pirfenidone nanofibers demonstrated wound healing acceleration on day 8, earlier than all tested groups.
UNASSIGNED: These findings highlight the potential of the drug-loaded nanofibrous system as a promising medicated wound dressing for diabetic foot applications.
摘要：
■糖尿病通常与足部溃疡有关，造成严重的健康风险和并发症。糖尿病患者伤口愈合受损归因于多种因素，包括高血糖,神经病,慢性炎症，氧化损伤，血管化减少。
■为了应对这些挑战，这个项目旨在开发生物活性，由聚乙烯吡咯烷酮组成的快速溶解纳米纤维敷料，其中含有抗生素（莫西沙星或夫西地酸）和抗炎药（吡非尼酮）的组合，使用静电纺丝技术防止细菌生长，减少炎症，加速糖尿病伤口的伤口愈合。
制备的载药纤维对于莫西沙星/吡非尼酮纳米纤维表现出443±67nm的直径,对于夫西地酸/吡非尼酮纳米纤维表现出488±92nm的直径。封装效率，莫西沙星/吡非尼酮纳米纤维的载药量和药物释放研究发现为70±3％和20±1µg/mg，分别,莫西沙星，96±6%和28±2微克/毫克，分别,对于吡非尼酮，两种药物在24小时内完全释放，而夫西地酸/吡非尼酮纳米纤维被发现是95±6%和28±2µg/mg，分别,对于夫西地酸和102±5%和30±2µg/mg，分别,对于吡非尼酮，夫西地酸的释放率为66%，80%，24小时后的吡非尼酮。使用诱导的糖尿病大鼠模型评估制备的纳米纤维制剂在加速伤口愈合中的功效。与对照组相比，所有测试的配方显示伤口更早完全闭合，这也得到了组织病理学评估的支持。值得注意的是,夫西地酸和吡非尼酮纳米纤维的组合在第8天显示伤口愈合加速，比所有测试组更早。
■这些发现突出了载药纳米纤维系统作为糖尿病足应用的有前途的药物伤口敷料的潜力。
■为了应对这些挑战，这个项目旨在开发生物活性，由聚乙烯吡咯烷酮组成的快速溶解纳米纤维敷料，其中含有抗生素（莫西沙星或夫西地酸）和抗炎药（吡非尼酮）的组合，使用静电纺丝技术防止细菌生长，减少炎症，加速糖尿病伤口的伤口愈合。
制备的载药纤维对于莫西沙星/吡非尼酮纳米纤维表现出443±67nm的直径,对于夫西地酸/吡非尼酮纳米纤维表现出488±92nm的直径。封装效率，莫西沙星/吡非尼酮纳米纤维的载药量和药物释放研究发现为70±3％和20±1µg/mg，分别,莫西沙星，96±6%和28±2微克/毫克，分别,对于吡非尼酮，两种药物在24小时内完全释放，而夫西地酸/吡非尼酮纳米纤维被发现是95±6%和28±2µg/mg，分别,对于夫西地酸和102±5%和30±2µg/mg，分别,对于吡非尼酮，夫西地酸的释放率为66%，80%，24小时后的吡非尼酮。使用诱导的糖尿病大鼠模型评估制备的纳米纤维制剂在加速伤口愈合中的功效。与对照组相比，所有测试的配方显示伤口更早完全闭合，这也得到了组织病理学评估的支持。值得注意的是,夫西地酸和吡非尼酮纳米纤维的组合在第8天显示伤口愈合加速，比所有测试组更早。
■这些发现突出了载药纳米纤维系统作为糖尿病足应用的有前途的药物伤口敷料的潜力。
